Investment Rating - The report maintains a "Buy" rating for the company, expecting the stock price to outperform the industry index by more than 15% in the next six months [4][21]. Core Views - The company is expected to see significant revenue growth driven by its overseas production capacity, particularly from the Thailand project, which is anticipated to improve profitability [11][12]. - Despite short-term pressure on profitability in 2024, the overall revenue is projected to maintain growth, with a notable increase in net profit expected in 2025 [2][12]. Financial Performance Summary - **Revenue**: The company reported a revenue of 797 million yuan in 2024, a year-on-year increase of 26.42%. The projected revenues for 2025, 2026, and 2027 are 1.406 billion, 1.762 billion, and 2.007 billion yuan respectively, indicating growth rates of 76.5%, 25.3%, and 13.8% [1][12]. - **Net Profit**: The net profit for 2024 is expected to be 56 million yuan, down 30.51% year-on-year, but is projected to rebound to 223 million yuan in 2025, reflecting a growth of 299.6% [1][12]. - **Cash Flow**: The net cash flow from operating activities decreased by 58.75% in 2024, primarily due to rising product costs and increased procurement expenses [3]. - **Profitability Ratios**: The company's net profit margin for 2024 is projected at 6.90%, down 5.71 percentage points from the previous year, while the return on equity (ROE) is expected to improve significantly to 12.0% by 2025 [2][12]. Market Position and Strategy - The company is recognized as a leading producer of mid-to-high-end flavoring agents in China, with a strong brand and customer resource base. It has established stable relationships with major international flavor companies [8][9]. - The global flavor and fragrance market is expected to grow steadily, with the market size projected to reach approximately 32.1 billion USD by 2025, driven by increasing demand in developing countries [9][10]. - The company's strategic move to expand its production capacity in Thailand is aimed at mitigating geopolitical risks and enhancing its competitive position in the global market [10][11].

Core Viewpoint - The company reported a mixed financial performance for 2024, with revenue growth but a significant decline in net profit, indicating challenges in maintaining profitability amidst competitive pressures in the market [1][2]. Financial Performance - In 2024, the company achieved a revenue of 797 million yuan, a year-on-year increase of 26.42%, while the net profit attributable to shareholders was 56 million yuan, down 30.51% year-on-year [1]. - The company's gross profit margin for 2024 was 25.52%, a decrease of 6.65 percentage points compared to the previous year [2]. - The net profit margin for 2024 was 6.90%, down 5.71 percentage points year-on-year, reflecting increased competition and reduced profit margins [2]. Cash Flow and Financial Health - The net cash flow from operating activities in 2024 was 31 million yuan, a decrease of 58.75% year-on-year, primarily due to rising product costs and increased procurement expenses [3]. - The net cash flow from investing activities was -284 million yuan, a decline of 433.73% year-on-year, attributed to the disposal of financial assets and investment returns [3]. - The net cash flow from financing activities increased to 133 million yuan, up 700.33% year-on-year, mainly due to increased bank borrowings [3]. Market Position and Product Offering - The company is a leading producer of mid-to-high-end flavoring agents in China, with a diverse product range including over 310 types of flavors, meeting various downstream application needs [4]. - The company has established stable relationships with major international flavor companies, ensuring a solid customer base and revenue growth [5]. - The global flavor and fragrance market is projected to grow, with the market size expected to reach approximately 32.1 billion USD by 2025, indicating a favorable environment for the company's growth [5][6]. Strategic Initiatives - The company is expanding its overseas market presence to mitigate geopolitical risks, with a new synthetic vanillin production line planned in Thailand [7]. - The Thai production facility has commenced full operations, contributing to performance growth, while domestic capacity expansion is underway [7]. - The company is adapting to new tariffs on imports, implementing a production adjustment plan to maintain competitiveness [7]. Future Outlook - The company is expected to achieve revenues of 1.406 billion yuan, 1.762 billion yuan, and 2.007 billion yuan for 2025-2027, with corresponding net profits of 223 million yuan, 294 million yuan, and 352 million yuan [8]. - The company is well-positioned to benefit from the expanding flavor and fragrance market and its new production capacities, leading to improved economic efficiency [8].

| 招商证券股份有限公司 | | | | | --- | --- | --- | --- | | 关于昆山亚香香料股份有限公司 | | | | | 保荐人名称：招商证券股份有限公司 | 被保荐公司简称：亚香股份 | | | | 联系电话：0755-83084021 保荐代表人姓名：覃建华 | | | | | 保荐代表人姓名：程建新 联系电话：0755-83084021 | | | | | 一、保荐工作概述 | | | | | 项目 工作内容 | | | | | （1）是否及时审阅公司信息披露文件 | | 是 | | | （2）未及时审阅公司信息披露文件的次数 | | | 无 | | （1）是否督导公司建立健全规章制度（包括但 | | | | | 不限于防止关联方占用公司资源的制度、募集资 | | | | | 是 | | | | | 金管理制度、内控制度、内部审计制度、关联交 | | | | | 易制度） | | | | | （2）公司是否有效执行相关规章制度 | | 是 | | | （1）查询公司募集资金专户次数 | | 8次 | | | （2）公司募集资金项目进展是否与信息披露文 | | | | | 是 | ...

Core Viewpoint - The company has experienced significant revenue growth in 2024, but net profit has declined due to intense price competition in the spice industry [2] Group 1: Financial Performance - In 2024, the company achieved a revenue of 797 million yuan, representing a year-on-year increase of 26.42%, while net profit attributable to shareholders was 56 million yuan, down 30.51% [2] - In Q1 2024, the company reported a record revenue of 262 million yuan and a net profit of approximately 82.17 million yuan, with a non-recurring net profit of 38.20 million yuan, marking a year-on-year growth of 120.8% [2] Group 2: Production Capacity and Expansion - The first phase of the "Yaxiang Biotechnology (Thailand) Co., Ltd. Production Base Project" commenced production in November 2024, with the Thai factory achieving normal full-load production [2] - The first phase capacity includes 1,000 tons of vanillin, 200 tons of oak moss, and other products, with a second phase expected to be completed around August 2025 [3] - A new synthetic vanillin production line is planned in Thailand, which will have an annual capacity of 4,000 tons [3] Group 3: Strategic Investments - The company plans to acquire 10% equity in Centrome Inc. for 30 million USD to expand sales channels and market share in the U.S. [3] - This investment is expected to enhance the company's international influence and complement its U.S. subsidiary's operations [3] Group 4: Market Strategy - The establishment of the Thai base allows the company to diversify its product structure and increase production capacity while avoiding tariff impacts [4] - The company is actively exploring new product layouts to meet diverse market demands, including the introduction of ambroxan, a fragrance ingredient commonly used in perfumes [4]

Group 1: Financial Performance - The company's net profit for 2024 is expected to decline due to four main factors: increased fixed asset depreciation, a 37% year-on-year increase in sales team size leading to higher sales expenses, increased R&D investment, and a structural decline in gross margin of core products due to intensified market competition [2][3] - In Q1 2025, the company reported a net profit growth of approximately 360%, attributed to investment income of about 40 million yuan and the efficient operation of the Thai production base [3] Group 2: Operational Insights - The Thai factory achieved approximately 90 million yuan in revenue and 19 million yuan in net profit in Q1 2025, primarily producing vanillin and cooling agents [3] - Long-term contracts account for about 80% of the company's total revenue, with pricing strategies adjusted based on market supply and demand dynamics [3][4] Group 3: Expansion and Product Development - The first phase of the Thai base is fully operational, with the second phase expected to be completed around August 2025, and the third phase in preliminary planning [3] - The company is actively exploring new product developments, such as ambroxan, to meet diverse market and consumer demands [4] - Strategic investment in ABT shares aims to strengthen sales channels and enhance market competitiveness [4]

Financial Performance - In Q1 2025, the company achieved operating revenue of 97.79 million, a year-on-year increase of 24.06% [2] - The net profit attributable to shareholders in Q1 2025 was 11.45 million, reflecting a year-on-year growth of 94.50% [2] - For the full year 2024, the company reported operating revenue of 345.18 million, up 28.12% compared to the previous year [3] - The net profit attributable to shareholders for 2024 was 22.09 million, showing a significant increase of 659.83% [3] Strategic Focus - The company plans to enhance its core competencies in product innovation, brand strength, and quality control to drive future profitability [4] - Emphasis will be placed on market-oriented R&D, focusing on technology iteration, new product development, and quality improvement [3] Market Challenges - The ongoing US-China tariff conflict has had a measurable impact on the company's performance [4] - The company is actively exploring new regional markets to reduce reliance on any single market and mitigate tariff impacts [5] - Strategies include enhancing internal management and cost control to improve product competitiveness [5] R&D Investment - The company is committed to increasing R&D investment to foster technological breakthroughs and product innovations [3] - Future R&D efforts will focus on optimizing management systems, enhancing innovation efficiency, and developing new technologies in emerging sectors [3]

Group 1: Investor Relations Activities - The company held an earnings briefing on April 30, 2025, via an online platform, with participation from various investment firms [2] - Key attendees included the company's chairman, general manager, and financial director [2] Group 2: Company Development and R&D - The company focuses on R&D in natural flavors, collaborating with Shanghai University of Applied Technology to develop unique flavor products [3] - It has established partnerships with renowned companies like Firmenich and Givaudan, enhancing its competitive edge [3] - The company is recognized as a national high-tech enterprise and has multiple certifications, including ISO9001:2015 and FDA certification [3] Group 3: Production Capacity and Market Growth - The company plans to produce 2,600 tons of cooling agents and flavor raw materials, which will stabilize production and reduce costs [4] - Increased product variety from new projects is expected to enhance competitive advantage and profitability [4] Group 4: Revenue Growth Factors - Revenue growth in 2024 is attributed to expanded domestic and international market efforts, with participation in industry exhibitions [6] - The company is actively increasing its international market share through strategic engagements [7] Group 5: Technological Advantages - The company holds several core technologies, including WS-23 production technology, with a raw material utilization rate exceeding 87% [8] - Over 70% of the main business revenue comes from core technology products, establishing the company as a leader in the cooling agent sector [8] Group 6: Market Position and Stock Valuation - The company emphasizes value management and believes that focusing on core business and performance will drive market value [9] - It aims to enhance core competitiveness to provide long-term returns to investors [9] Group 7: Risk Management Strategies - The company monitors market dynamics and adjusts production strategies to mitigate risks associated with market demand fluctuations [11] - It plans to optimize marketing strategies to improve sales levels and expand business areas [11] Group 8: Long-term Strategic Projects - The first phase of the fundraising project is currently in trial production and is expected to strengthen market influence in the long term [12] - The project aims to solidify the company's leading position in the cooling agent market [12]

Financial Overview - The company achieved significant growth in Q1 2025, with total revenue reaching 262 million yuan, a year-on-year increase of 50.28% [1] - The net profit attributable to shareholders was 82.17 million yuan, a substantial year-on-year increase of 361.70% [1] - The net profit after deducting non-recurring items was 38.20 million yuan, reflecting a year-on-year growth of 120.80% [1] Profitability Analysis - The company's gross margin was 31.58%, an increase of 18.52 percentage points year-on-year [2] - The net profit margin reached 31.35%, showing a significant year-on-year increase of 210.16 percentage points [2] - This indicates notable improvements in product value addition and service quality [2] Cost and Expenses - Despite revenue and profit growth, the proportion of the company's three expenses (selling, administrative, and financial expenses) to revenue increased from 9.46% in the same period last year to 12.68%, a rise of 34.05% [3] - This suggests potential pressure on cost control during operations [3] Asset and Liability Situation - As of the end of the reporting period, the company's cash and cash equivalents amounted to 256 million yuan, a decrease of 31.57% year-on-year [4] - Accounts receivable increased to 292 million yuan, a year-on-year growth of 44.09%, with accounts receivable to profit ratio reaching 524.82%, necessitating close monitoring of collection [4] - Interest-bearing liabilities also increased to 345 million yuan, a year-on-year rise of 73.42% [4] Per Share Indicators - The net asset per share was 21.20 yuan, a year-on-year increase of 9.17% [5] - Earnings per share were 1.02 yuan, reflecting a year-on-year growth of 363.64% [5] - Operating cash flow per share was 0.49 yuan, a significant year-on-year increase of 405.36% [5] Business Model and Financing Dividends - The company's performance primarily relies on R&D, equity financing, and capital expenditures [6] - Since its listing, the total financing amount has reached 727 million yuan, with total dividends distributed amounting to 40.40 million yuan, resulting in a dividend financing ratio of only 0.06 [6] - Overall, while the company showed excellent performance in Q1 2025, the rising expense ratio and rapid growth in accounts receivable warrant further attention from investors [6]

证券代码：603020 证券简称：爱普股份 公告编号：2025-021 爱普香料集团股份有限公司 2025 年第一季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号---行业信息披露 第十 四号---食品制造》的相关规定，现将爱普香料集团股份有限公司(以下简称"公 司")2025 年第一季度主要经营数据（未经审计）公告如下： 一、报告期经营情况 1、按照产品类别分类情况 单位：万元 币种：人民币 | 产品类别 | 2025 年第一季度 | 2024 年第一季度 | 同比变动(%) | | --- | --- | --- | --- | | 香精 | 15,946.00 | 15,324.58 | 4.06 | | 香料 | 3,663.69 | 4,731.35 | -22.57 | | 食品配料 | 40,565.31 | 54,103.62 | -25.02 | | 小计 | 60,175.00 | 74,159.55 | -18.86 | 2、按照销售 ...

证券代码：920016 证券简称：中草香料 公告编号：2025-048 安徽中草香料股份有限公司 三、 投资者关系活动主要内容 在本次投资者关系活动中公司向各位投资者简要介绍了公司的基本情况、 主营业务、产品特性等内容。本次投资者关系活动的主要问题及问题回复概要 如下： □业绩说明会 □媒体采访 √现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 1、公司 2024 年度产品收入构成 关于投资者关系活动记录表的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 √特定对象调研 二、 投资者关系活动情况 活动时间：2025 年 4 月 26 日 活动地点：安徽中草新材料有限公司会议室、厂区 参会单位及人员：洪顺资本、申万宏源研究、东北证券（以上排名不分先后） 上市公司接待人员：董事、董事会秘书赵娅女士 回答：公司产品可以分为凉味剂系列、合成香料系列、天然香料系列，可 以应用于食品、饮料、日化、医药、烟草、饲料等领域，公司产品基本流向产 业链下游企业。 5、预计何时释放新 ...